Japanese Journal of Clinical Oncology 32:48-53 (2002)
© 2002 Foundation for Promotion of Cancer Research
A Feasibility Study of Paclitaxel 225 mg/m2 and Carboplatin AUC = 6 in Untreated Advanced Non-small Cell Lung Cancer Patients in Japan
1Department of Internal Medicine, National Kinki-Central Hospital for Chest Diseases, Sakai, Osaka and 2Division of Biostatistics, Toyama Medical and Pharmaceutical University, Toyama, Japan
Background: The combination of paclitaxel (225 mg/m2, 3 h infusion) and carboplatin [area under the curve (AUC) 6 mg/mlxmin] is used widely for non-small cell lung cancer in the USA and is one of the standard regimens in the Southwest Oncology Group. In Japan, however, the upper limit of the approved dose for single-use paclitaxel is 210 mg/m2 and the optimum dose of this agent in combination with carboplatin has not yet been established. This study was designated to determine whether the paclitaxel dose of 225 mg/m2 plus carboplatin (AUC = 6) is tolerable for Japanese patients with untreated advanced non-small cell lung cancer.
Methods: Ten patients were enrolled between October 1999 and June 2000 and all of these patients were evaluable for toxicity. Chemotherapy consisted of carboplatin (AUC = 6 mg/ml xmin) and 225 mg/m2 of paclitaxel on day 1 every 3 weeks.
Results: Neutropenia was the major toxicity and grade 4 neutropenia was observed in seven of the 10 patients (70%), but febrile neutropenia was not observed. Grade 4 anemia as a dose-limiting toxicity was observed in two patients. This was due to gastric ulcer bleeding in both patients. Only one patient experienced grade 3 peripheral neuropathy. No grade 3 or more myalgia or arthralgia was reported. Overall, 44 courses of chemotherapy were administered in 10 patients. Partial responses were observed in six of the 10 patients (60%). Median survival time was 7.7 months.
Conclusion: Paclitaxel at 225 mg/m2 in a 3 h infusion and carboplatin AUC = 6 appears to be tolerable in Japanese patients with untreated advanced non-small cell lung cancer.
+ For reprints and all correspondence: Mitsumasa Ogawara, Department of Internal Medicine, National Kinki-Central Hospital for Chest Diseases, 1180 Nagasone-cho, Sakai, Osaka 591-8555, Japan. E-mail: ogawaram@kinchu.hosp.go.jp
Abbreviations: NSCLC, non-small cell lung cancer; SWOG, Southwest Oncology Group; ECOG, Eastern Cooperative Oncology Group; AUC, area under the concentration–time curve; MST, median survival time; MTD, maximum tolerated dose; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; G-CSF, granulocyte colony-stimulating factor; DLT, dose-limiting toxicity; CR, complete response; PR, partial response; NC, no change; PD, progressive disease; NE, not evaluable; ORR, overall response rate; CBDCA, carboplatin